Mental health specialist video consultations versus treatment as usual in patients with depression or anxiety disorders in primary care: study protocol for an individually randomised superiority trial (the PROVIDE-C trial)

Markus W. Haun (markus.haun@med.uni-heidelberg.de)
Heidelberg University
https://orcid.org/0000-0003-1851-3747
Justus Tönnies
Heidelberg University
Regina Brinster
Heidelberg University
Dorothea Weber
Heidelberg University
Michel Wensing
Heidelberg University
Joachim Szecsenyi
Heidelberg University
Markus Vomhof
University of Duesseldorf
Andrea Icks
University of Duesseldorf
Beate Wild
Heidelberg University
Mechthild Hartmann
Heidelberg University
Hans-Christoph Friederich
Heidelberg University

Keywords: primary care, integrated care, telepsychiatry, videoconferencing, depression, anxiety

DOI: https://doi.org/10.21203/rs.3.rs-64848/v1
Abstract

Background: The majority of people with mental disorders, including those with severe and chronic disorders, are treated solely by their general practitioner (GP). Nevertheless, specialised mental health care may be required for specific patients. Notably, the accessibility of mental health specialist care is mainly complicated by (a) long waiting times for an appointment with specialists, (b) long travel distances to specialists, particularly in rural and remote areas and (c) patients’ reservations about mental health specialist care (including fear of being stigmatised by seeking such care). To mitigate those barriers, technology-based integrated care models have been proposed. The purpose of this study is to examine the effectiveness and cost-effectiveness of a mental health specialist video consultations model versus treatment as usual in patients with depression or anxiety disorders in primary care.

Methods: In an individually randomised, prospective, two-arm superiority trial with parallel group design, \( N = 320 \) patients with anxiety and/or depressive disorder will be recruited in general practices. The intervention includes a newly developed treatment model based on video consultations with focus on diagnostics, treatment planning, and short-term intervention by mental health specialists. We will systematically compare the effectiveness, cost-effectiveness, and adverse effects of this new model with usual care by the GP: The primary outcome is the absolute change in the mean depressive and anxiety symptom severity measured on the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS) from baseline to 6 months after baseline assessment. Follow-up in both groups will be conducted by blinded outcome assessors at 6 months and 12 months after baseline. The main analysis will be based on the intention-to-treat principle. We will optimise the likelihood of treatment effectiveness by strict inclusion criteria for patients, enhanced intervention integrity, and conducting a process evaluation.

Discussion: To the best of our knowledge, this is the first confirmatory study on a video-based, integrated care model for the treatment of anxiety and depressive disorders in GP patients in Germany.

Trial registration: ClinicalTrials.gov, United States National Institutes of Health (NCT04316572, https://clinicaltrials.gov/ct2/show/NCT04316572). Prospectively registered on 20 March 2020.

Background

Background and rationale

Major depression and anxiety disorders are highly prevalent with 4.4% and 3.6% of people respectively being affected worldwide [1]. Both entities are among the top ten leading causes of global years lived with disability [2]. Many patients with mental health problems can be effectively treated in primary care, but specific patients need specialised mental health care. While effective treatment options are available [3], accessibility to mental health specialist care remains problematic even in Western health care systems due to (a) long waiting times for appointments with specialists [4–6], (b) long travel distances to specialists, particularly in rural and remote areas [7], and (c) patients’ reservations about mental health specialist care (including fear of being stigmatised by seeking such care) [8]. Furthermore, given the rising
number of patients struggling with multimorbidity including mental disorders in an aging society, more integrated health care concepts are urgently needed [9]. At present, the majority of people with mental disorders, including those with severe and chronic disorders, are treated solely by their general practitioner (GP) [10–12]. While this can be highly effective and some patients prefer to be treated by their own GP, as their GP witness their medical history providing truly personalised health care [13], a significant number of patients suffering from mental health conditions, particularly those with somatic comorbidity, are not recognised, do not receive adequate treatment or need specialised mental health care [14–16]. While most GPs commit themselves to comprehensive care of both medical diseases and psychosocial distress, due to the “somatisation effect” in doctor-patient interaction in primary care, they may emphasise the assessment and treatment of somatic symptoms [17, 18].

To mitigate those problems, one promising approach comprises the integration of mental health specialists’ (MHS) expertise in timely diagnostics and therapy in the easily accessible and familiar environment of primary care [19]. Such an approach supports the tailored treatment for patients initially presenting to their GP. In practice, two principal models have been implemented and evaluated in high income countries. First, the Collaborative Care (CC) model in which the GP is supported by a case manager who tracks patients per telephone, conducts psychological assessments, and reviews cases with an MHS, often a psychiatrist [20, 21]. The MHS supervises the case manager and intervenes, if necessary, by prescribing drugs or scheduling face-to-face contacts. This time-saving model reaches a higher number of patients in specialised mental care than the usual referral-based system as the MHS is not required to see all patients regularly. Second, the Primary Care Behavioural Health (PCBH) Model is a team-based approach that co-locates the MHS with the primary care team [19, 22]. Specifically, the MHS routinely provides high volume services embedded in the primary care practice team. One example is the Cherokee Health Systems, which is a complete community health system in Tennessee in the United States (https://www.cherokeehealth.com) [23]. Often MHS attend to patients through “warm handoffs” from the GP instead of receiving conventional referrals. This model provides a low-threshold access to specialised care and has been well accepted in patients and providers [24]. Both the CC and the PCBH model have been implemented successfully in health care practice [25–27]. However, small and remote practices struggle to implement these models due to too limited resources to employ additional staff, e.g. MHS as case managers. In most European health care systems, such as the one in the United Kingdom, in France, or in Germany, where the mean number of physicians per practice is much lower (predominance of single-handed practitioners) than in the US, the barriers of implementation are even higher [28, 29]. Consequently, it is crucial to investigate potentially more feasible modes of delivery for putting these integrated care models into practice.

As an innovative, technology-facilitated approach to integrated care, real-time video consultations conducted by MHS are increasingly considered to be alternative or complementary to in-person settings [30]. We conducted a brief systematic literature review (searching MEDLINE from inception to June 11th, 2020 using the search strings in Additional file 1) on the current evidence on video-based integrated mental health care for depression and anxiety disorders. We found seven systematic reviews among the 2,314 records screened which investigated the effectiveness of telepsychiatry models integrating mental care.
health services into primary care [30–36]. These models not only yield reliable treatment outcomes comparable to those achieved in traditional in-person settings but also allow patients – particularly those in rural or underserved areas and those suffering from multimorbidity – to access mental health treatment more easily. However, many randomised controlled trials evaluating such models have been conducted either in highly structured contexts, e.g. the US Veterans Health Care Administration [37, 38] or included patients from inpatient health care settings [39]. Hence, the generalisability of those results on effectiveness to primary health care systems in many other countries (e.g., those predominated by single-handed practitioners) remained unclear.

The research group PROVIDE (ImPROving cross-sectoral collaboration between primary and psychosocial care: An implementation study on VIDEo consultations, https://www.provide-project.de/ziel-konzept/?lang=en), funded by the German Federal Ministry of Education and Research, focuses on innovative modes for delivering primary care mental health. To explore whether and how mental health specialist video consultations (MHSVC) can be implemented in routine primary care in Germany, i.e. a prototype single-handed practitioner system in particular, we conducted a randomised feasibility trial (PROVIDE-B) enrolling 50 patients with depression and/or anxiety between February and October 2019 [40]. In this feasibility trial, acceptability of MHSVC in terms of treatment retention (87.0%) and attendance at sessions (94.4%) was high. Moreover, the nested qualitative study showed that satisfaction was high both in patients and health professionals [41]. Study procedures, e.g. inclusion process, data collection, study monitoring, and appointment management proved to be feasible. Therefore, as the next step a sufficiently powered randomised controlled effectiveness trial was planned.

**Objectives**

The PROVIDE-C randomised controlled trial (RCT) aims to evaluate whether MHSVC integrated into primary care is a clinically effective and economically efficient treatment in patients presenting with depression and anxiety in comparison to usual care. This paper presents the study protocol for the trial, adhering to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Statement [42] (see Additional file 2 for the checklist), while the results of the trial will be reported in line with the CONSORT 2010 Statement for Social and Psychological Interventions Statement (CONSORT-SPI 2018) [43].

The primary objective of the PROVIDE-C trial is to study whether MHSVC care compared to treatment as usual is superior in treating primary care patients with depression and/or anxiety. The primary outcome measure is absolute change in depression and anxiety symptom severity at 6 months after baseline assessment. Secondary objectives are to: (1) test whether individuals in the intervention arm differ from individuals in the comparison arm in depressive and anxiety symptom severity at 12 months follow-up, burden of specific somatic complaints, recovery (defined as “the personal process of adaptation and development through which the individual overcomes the negative personal and social consequences of [a] mental disorder and regains a self-determined and meaningful life” [44]), health-related quality of life, quality and patient-centredness of chronic illness care, and adverse effects at six and 12 months and (2)
evaluate the cost-effectiveness of the primary care embedded MHSVC model of care compared to usual care.

**Trial design**

PROVIDE-C is a multicentric, prospective, superiority and assessor blinded RCT with stratified individual randomisation and two parallel arms. Participants will be randomised to the MHSVC intervention or usual care arm with 1:1 allocation, stratified by general practice and depressive and anxiety symptom severity (Patient Health Questionnaire Anxiety and Depression Scale, PHQ-ADS [46]; three levels: mild, moderate, severe).

**Methods**

**Trial setting**

The main setting of this trial will be general practices in Germany. We will include general practices in the federal states of Baden-Wuerttemberg, Hesse, and Rhineland-Palatinate (overall population: 21.5 million; overall area size: 75,000 km²). During the internet-based video consultation, the patient will be in the general practice, while the MHS will conduct the consultation from an offsite location.

**Patient and public involvement**

During the planning phase of the study, we involved two patient partners (one female, one male) who had received video consultations in the PROVIDE-B feasibility trial. Specifically, the patient partners participated in the conceptualisation of the trial procedures and materials. They revised the draft versions of this study protocol and all trial materials including information sheets, consent materials, and the questionnaire sets with extra regard to clarity and understanding from the service user perspective. We will continue to involve these two patient partners during the trial accounting for guidance for public involvement in research [45]. Both patient partners are compensated for their expenses.

**Inclusion and exclusion criteria**

**Primary care practices and mental health specialists**

For the primary care practices, inclusion criteria are as follows: 1) primary care practice (licensed GP), 2) readiness of the team to familiarise patients with video consultation system, and 3) written informed consent. For MHS, inclusion criteria are as follows: 1) psychologists with a diploma/master's degree or medical doctors, 2) licensed psychotherapist or advanced trainee with passed intermediate examination in psychotherapy and at least 1,200 hours of treatment experience (three years of training), and 3) written informed consent. Exclusion criteria for the practices and the MHS are lack of a designated room for the video consultations to ensure confidentiality and lack of internet access or low bandwidth (< 384 kbps).

**Patients**
Inclusion criteria require patients to 1) meet at least one of the following mental conditions: i) at least moderately severe depression, defined as a Patient Health Questionnaire–9 (PHQ-9) [46] score of 10 or greater with either item one and/or two being endorsed, ii) at least moderately general anxiety disorder, defined as a Generalized Anxiety Disorder Scale (GAD-7) [46] score of 10 or greater, or iii) a combined anxiety and depression score (PHQ-ADS) of 12 or greater, 2) currently have no or as yet insufficient psychosocial treatment (psychotherapy, psychopharmacotherapy, or both) or difficulty with adherence, 3) agree to participate in the study by written informed consent, 4) be capable of giving consent, and 5) be 18 years or older. Exclusion criteria are as follows: 1) substance abuse/dependence that is likely to compromise intervention adherence, 2) risk of endangerment to others and/or risk of self-endangerment, 3) need for emergency medical treatment, e.g. admission, 4) acute psychotic symptoms, e.g. persecutory delusions and/or thought insertion, 5) severe cognitive impairment or dementia, 6) significant hearing and/or visual impairment, 7) pregnancy in the ≥ 2nd trimester, 8) insufficient German language proficiency, and 9) prior experience with video consultations through participation in the PROVIDE-B feasibility trial.

**Intervention**

**Intervention arm**

The PROVIDE-C intervention is a targeted primary care-based mental health service that combines elements of the collaborative care and consultation-liaison model [20, 47]. Specifically, the intervention features web-based, real-time video consultations involving a live two-way interactive video to a primary care practice between MHS and patients. The intervention includes three core processes (“active ingredients”) for effective primary care-based mental health care, namely systematic diagnosis plus proactive monitoring using validated clinical rating scales, the establishment of an effective working alliance, and a stepped-care algorithm within integrated care adjusting treatments based on clinical outcomes. If indicated, the PROVIDE-C intervention also includes brief psychotherapy that works with interpersonal dynamics and that has been shown to confer additional benefit [21]. The intervention follows a transdiagnostic treatment approach for emotional disorders (depression and anxiety), for which various meta-analyses have shown the efficacy compared to control conditions on measures of overall anxiety, disorder-specific anxiety, and depression [48, 49]. In addition, the intervention entails elements from problem-solving therapy, which has been shown to yield moderate effects in alleviating depression and anxiety in primary care [50]. Psychodynamic elements following a relationship focus and interpersonal understanding are added to foster the working alliance that has been promoted as a crucial element of manuals achieving high acceptability in both patient and clinicians [51]. Applying a stage model of psychotherapy manual development [52], we had initially compiled a stage I intervention manual delineating treatment techniques, goals, and format. For the PROVIDE-C trial, we have refined this manual to a stage II intervention manual. For description of the intervention, we follow the TIDieR guidance (see Additional file 3) [53].
Patients will receive their first video consultation shortly after randomisation and will be scheduled for five sessions, lasting 50 minutes each, in biweekly intervals. The video consultations will be carried out on a secure (i.e. encrypted), web-based secure videoconferencing platform on a subscription basis (arztkonsultation ak GmbH, https://arztkonsultation.de) at fixed time slots which general practice staff and therapists will have agreed on. At the beginning of each consultation, a practice team member will escort the patient to the room designated for video consultations, set up the widescreen (12.3-inch) computer tablet and the videoconferencing platform, if applicable, address the patient's questions, and then leave the room. After the third session, we will conduct an interim monitoring of the symptoms (using the PHQ-ADS) and feedback these results to the therapist. After the final consultation with the patient the MHS will send a written case summary to the GP which will be attached to the medical record in the primary care practice and on which, if needed, further decisions on follow-up procedures between GP and MHS can be based. During the trial, the MHS will receive biweekly group supervision led by a senior consultant specialised in both psychiatry and psychosomatic medicine from the Department of General Internal Medicine and Psychosomatics, Heidelberg University.

**Comparison arm**

Patients allocated to the control group will get the usual care provided by the GP. This may or may not include a referral to an MHS. We expect that most people with depression and/or anxiety disorders are currently treated by their GP only. GPs tend to provide brief counselling and prescribe psychotropic medication rather than conduct psychotherapy as laid out in guidelines [15, 54, 55]. Only every fifth patient with depression is referred to specialised care [11]. There will be no restrictions to the usual treatment by the GP.

**Modifications**

We anticipate no substantive modifications of the intervention, since it was piloted and subsequently adapted as part of the feasibility. The assessment will determine if the adverse event was related directly to the PROVIDE-C intervention or other circumstances not intervention related.

**Concomitant care**

In both arms, participants will be permitted to continue any treatment they were engaged with at entry to the trial. For exceptions see exclusion criteria. We will assess concomitant care via self-report questionnaire and routinely collected general practice data.

**Intervention integrity**

We formulated the following core intervention components [56]: (1) video consultations by mental health specialists, (2) specialist diagnostics, (3) fixed dose of five video consultations of 50 minutes each for each patient over a period of approximately eight weeks, (4) interventions focus primarily on affect expression and regulation, and (5) specialist supervision [57–59]. Concerning intervention integrity, we consider criterion (1) as fulfilled through the recruitment of MHS, criterion (2) as fulfilled if the general practice has received a standardised diagnostic report after the 2nd video consultation, criterion (3) as
fulfilled if the number of video consultations in the intervention log encounters kept in trial coordination centre corresponds with the prespecified default, and criterion (5) as fulfilled if the number of supervisions sessions in the log encounters corresponds with the prespecified default. We will assess the adherence to criterion (4) by requesting the therapists to fill in an online self-assessment questionnaire at the end of each video consultation. Notwithstanding, we will continuously monitor and foster intervention integrity, e.g. by reviewing treatment progress in the regular supervision. However, we consider this study as a pragmatic trial in a real world service setting, so that – as part of local modifications/adaptions – the MHS are not expected to follow the manual exactly but may work according to their own judgment of what fits with patient characteristics to some extent [60]. In the control arm, to compare usual care before and during participation in the trial, information about health service use will be collected at each study assessment.

**Outcomes**

We will collect patient-reported outcome measures at baseline just prior to randomisation and at six- and 12-months post randomisation. These timepoints are frequently applied in trials of complex mental health interventions and will permit comparisons to be drawn with prior related trials.

**Primary Outcome**

The primary outcome of this trial is the absolute change in mean depressive and anxiety symptom severity on the PHQ-ADS [61–63] from baseline to 6 months after baseline assessment [64]. We will apply the PHQ-ADS score from the screening for computing the PHQ-ADS change score, if the baseline assessment has been performed no later than 28 days after screening. The PHQ-ADS is a composite score containing the items from the PHQ-9 and the GAD-7 [46]. To account for the often nonepisodic nature of affective disorders in primary care [65], we selected symptom severity as the outcome measure rather than a clinical diagnosis.

**Secondary Outcomes**

Secondary outcomes include differences of the absolute change in mean depressive and anxiety symptom severity on the PHQ-ADS at 12 months between both study arms. At 6 and 12 months after baseline assessment, we will also calculate the absolute change in mean depressive and anxiety symptom severity on the PHQ-9 and GAD-7, respectively along with differences in mean burden of specific somatic complaints (Somatic Symptom Disorder–B Criteria Scale, SSD-12 [66]), recovery (Recovery Assessment Scale, RAS-G [44]), health-related quality of life (SF-12 questionnaire [67], and EQ-5D 5L [68]), quality and patient-centredness of chronic illness care (Patient Assessment of Chronic Illness Care–Short Form, PACIC–Short Form [69]), adverse effects (Inventory for the Assessment of Negative Effects of Psychotherapy, INEP [70]), and health service use (Questionnaire for the Assessment of Medical and non-Medical Resource Utilisation in Mental Disorders, FIMPsy [71]) between both study arms. The cost-effectiveness of the primary care embedded MHSVC model of care compared to usual care over the study period will comprise additional secondary outcomes.
Sample size calculation

Based on the review of the existing evidence, especially of published, sufficiently powered RCTs in the areas of collaborative care [20] and integrated mental health [31, 34, 72] and opinion-seeking within the study team, we chose the absolute change in depressive and anxiety symptom severity on the continuous PHQ-ADS scale from screening (t1) or, if the baseline assessment has been performed later than 28 days after screening, baseline (t0) to six months after baseline assessment (t2 = t1 + 6 months or t2 = t0 + 6 months, respectively) to be the primary outcome of clinical relevance for patients and health policy makers. For this scale, a reduction of 3 to 5 points is considered clinically relevant and we expect a standard deviation of 9 points [63]. If this reduction is not achieved under the optimised study conditions, it is unlikely that even a minimal significant effect according to Cohen (\(d = 0.2\)) will be achieved under routine conditions [73]. Statistical tests will be performed at a two-sided significance level of \(\alpha = .05\) with a power of \(1 - \beta = .80\). With these parameters, a sample of \(N' = 292\) was obtained. The sample size calculation was performed using PASS 16.0.3. Adjusted for a correlation parameter between baseline and the difference between baseline and post-assessment of \(k = 0.35\) (for both intervention and control group) and taking into account 20% loss-to-follow-up (\(m = 0.20\)) (based on a large study on case management of depression by medical assistants in small German general practices [27]), the required sample size is \(N = (N'^* (1 - k^2))/(1 - m) = 314\). For the sake of simplicity, the planning assumes \(N = 320\) patients (see Fig. 1 for the study flowchart).

Recruitment

In total, we plan to enrol 320 patients of whom approximately 50% will be allocated to the MHSVC intervention arm. Due the large effort to provide MHSVC for that number of patients at once, we will recruit in three consecutive recruitment waves of approximately six months duration and 107 enrolled patients each. Per wave we will enrol approximately ten general practices, so that each of them will recruit ten to twelve patients on average.

Study site: General practices

Overall, 30 general practices will be recruited in this trial. First, we will seek to recruit practices by contacting the GPs who expressed interest and/or participated in preceding preimplementation and feasibility studies of the PROVIDE project [18, 40]. Second, we will recruit through the network of collaborating academic research practices affiliated with the Department of General Practice and Health Services Research at Heidelberg University. Finally, we will use contact information from publicly available data bases and registers of the State Board of Physicians of Baden-Wuerttemberg, Hesse, and Rhineland-Palatinate. In those data bases, all within the respective region practising physicians are registered. We will contact practices by mail to introduce the study and establish interest. We will then visit interested practices (1) to underscore how the trial fits with the goals of patient-centred general practice, (2) to evaluate eligibility, (3) to clearly outline the trial and how its procedures may affect the work of the practice, (4) to gain consent to participate, (5) to agree on the regular time slots for the
consultations, (6) to hand out the tablet and introduce the videoconferencing platform, and (7) to schedule a virtual get-together between the practice team and the MHS assigned to the practice. Moreover, we will dispense jointly designed brochures and position waiting room posters both tailored to the respective practice. Finally, we will provide practices with a handbook outlining the trial, its procedures (including the handling of the videoconferencing platform), and feasible contingency plans in case of technical failures. This process will continue until enough practices are recruited to obtain the required sample size. We will not enrol any practices prior to obtaining the signed informed consent.

Mental health specialists

We will recruit the MHS at the Institute for Psychotherapy, Heidelberg (HIP), which is a state-approved psychotherapeutic training facility at Heidelberg University Hospital. We will contact all lecturers licensed as psychotherapists and all trainees systematically using mailing-lists. All interested individuals will have to apply and will then be invited for a short interview. The final decisions on the participating psychotherapists will be made by mutual discussion and consensus formation in the study team. In total, we will recruit at least 30 psychotherapists or psychotherapy trainees, that is, psychologists in the advanced training period. Each general practice will permanently work together with one MHS only. MHS may participate in more than one recruitment wave. The MHS will participate in the trial as freelancers and will be paid per session according to the current fees for psychotherapy as reimbursed by the German statutory health insurance. For all MHS, expected time expenditure will be approximately five hours per week (four hours for consultations, one hour for supervision). All participating MHS will receive a 3-hour introductory training, in which we will (1) obtain written informed consent, (2) outline the trial procedures, (3) familiarise MHS with the intervention by walking them through the manual and introducing the context of primary care, and (4) give a step-by-step instruction on conducting video consultations (e.g., room setup and videoconferencing platform,) to foster technical competency which is regarded as crucial for implementing telepsychiatry services [34].

Primary care patients

General practitioners will recruit patients during their regular clinic hours or by calling them at home. Based on their clinical judgment, GPs will prospectively select individuals suspected to suffer from depression and/or anxiety and introduce the trial to them by offering information material. We piloted all trial materials and procedures in the feasibility trial concerning user-friendliness. If the patient is interested in participation, she or he will receive the informed consent form and the baseline questionnaire from the GP. The practice team will forward the patient’s contact details to the study team who will screen her or him with respect to the eligibility criteria in a standardised Computer Assisted Telephone Interview (CATI). At that point, patients will be able to raise questions with the principal investigator who will answer them. The trial participation requires a signed informed consent which the patients will mail back to the trial coordination centre together with the baseline questionnaire. Whenever inclusion is not possible, we will record the reason, the general practice along with patient age and gender. For each patient, the individual intervention period will be three months. Based on our experience
from the feasibility trial, we anticipate participant recruitment to take place over approximately 18 months.

**Assignment of interventions**

**Allocation**

To minimise reporting and selection bias, baseline measures (PHQ-ADS, SSD-12, RAS-G, SF-12, PACIC–Short Form, FIMPsy, EQ-5D 5L) will be collected just prior to randomisation. Concerning the PHQ-ADS, however, we will apply screening values for computing the PHQ-ADS change scores, if the baseline assessment has been performed no later than 28 days after screening. After giving written informed consent, eligible participants will then be randomly assigned (1:1) to the intervention or comparison arm via a secure web-based randomisation system (Randomizer V.2.0.2; https://www.randomizer.at) operated by a data manager, not involved in the patient recruitment, centrally at the Institute of Medical Biometry and Informatics, Heidelberg University. Central randomisation will ensure concealment of the treatment sequence up to the allocation. The treatment sequence will be generated through a computer-generated sequence of random numbers. Randomisation will be stratified by general practice and symptom severity (PHQ-ADS; three levels: mild, moderate, severe).

**Masking**

Given the nature of this complex psychosocial intervention, neither GPs nor patients can be blinded to the patients’ allocation to either intervention or comparison arm. As part of the blind outcome assessment, research assistants, masked to participant allocation, will conduct the post-measurement in CATIs with the participants. We will make sure that the outcome assessors will not be present when discussing individual patients and avoid mentioning any names or assigned treatments. In addition, we will instruct patients before the interview not to mention which group, control or intervention, they belonged to. In the case of unintentional unblinding during the assessment, the assessors will document how, and at which point the unblinding unfolded. Hence, we will be able to subsequently determine the extent to which blinded assessment was successful.

**Data collection**

We will collect participant data from intervention and comparison arms at baseline just prior to randomisation and at six- and 12-months post randomisation (see Fig. 2 for the study schedule). We will use validated questionnaires presented via an online survey tool (Enterprise Feedback Suite (EFS) Survey, Questback GmbH) and inform all participants that if they decide to withdraw from the study, the data already provided will be retained and used in the analyses unless they request otherwise.

**Measures**

At baseline, we will assess demographic and clinical characteristics, including age, gender, marital status, education level, employment status, physical health status, chronic medical disease, history of
depression/anxiety, current and past psychiatric treatment/psychotherapy, current and past psychopharmacological treatment, willingness to accept psychotherapy, willingness to accept psychopharmacological treatment.

**Primary outcome**

Depressive and anxiety symptom severity will be assessed at each timepoint using the PHQ-ADS. The PHQ-ADS assesses the 16 symptoms of depression (9 items of the PHQ-9) and anxiety (7 items of the GAD-7) over the last two weeks using a 4-point Likert scale (where 0 = “not at all” and 3 = “nearly every day”). Overall sum scores are in the range of 0 to 48, with suggested cut points of 10, 20, and 30 indicating mild, moderate, and severe levels of depression-anxiety symptoms [61–63]. The PHQ-ADS is a validated diagnostic measure in primary care, with demonstrated efficacy and sensitivity as an outcome measure for treatment trials with a recommended minimally important difference of 3 to 5 points. [63]

**Secondary outcomes**

We will assess depression symptom severity and anxiety symptom severity separately using the PHQ-9 and the GAD-7, respectively, which both are subscales of the PHQ-ADS.

We will measure burden of specific somatic complaints using the SSD-12 [66, 74]. The SSD-12 comprises 12 items that require respondents to rate on a 5-point Likert scale how frequently they experience each cognition, emotion, or behaviour (from 0 = “never” to 4 = “very often”). Overall sum scores are in the range of 0 to 48 and provide a three-dimensional measure of the psychological criteria of DSM-5 Somatic Symptom Disorder. The SSD-12 displays high internal consistency (Cronbach's $\alpha = 0.94$) and good convergent validity, correlating well with measures of somatoform complaints, depression, and anxiety.

Recovery will be measured using the RAS-G [44]. The RAS-G includes 14 items that are rated on a 5-point Likert scale (from 1 = “totally disagree” to 5 = “strongly agree”). The mean scores for the five dimensions (Goal and Success Orientation, No Domination by Symptoms, Personal Confidence and Hope, Reliance on Others, Willingness to Ask for Help) are in the range of 1 to 5 with higher scores indicating better recovery. The RAS-G displays acceptable internal consistency (Cronbach's $\alpha$ from 0.59 to 0.88) and convincing convergent/discriminant validity, correlating positively with other measures of recovery and negatively with several psychopathology measures.

We will assess health-related quality of life using the SF-12 and EQ-5D 5L questionnaires [67, 68]. The SF-12 is a widely used general health questionnaire that consists of a mental component and a physical component and has demonstrated its psychometric robustness in numerous studies. Overall sum scores are in the range of 0 to 100 with higher scores indicating better quality of life. The EQ-5D 5L is a standardised instrument for measuring generic health status and comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression [68]. The patient rates each dimension on 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. To calculate quality-adjusted life years, the EQ-5D preference weights which are EQ-5D health states evaluated with a German tariff are combined with time [75].
The quality and patient-centredness of chronic illness care will be measured using the PACIC—Short Form which consists of 11 items with each item scored on a 5-point Likert scale (from 1 = “no/never” to 5 = “yes/always”) [69]. Overall mean scores are in the range of 1 to 5 with higher scores indicating better outcomes. The PACIC-Short Form has high internal consistency (Cronbach’s $\alpha = 0.87$) and convergent validity with the established 20-item PACIC.

We will measure adverse effects using the INEP [70]. The INEP comprises 21 items that are rated in a 7-step bipolar format ($-3 = “denitely a negative effect”$ to $3 = “denitely a positive effect”$) to detect not only deteriorations but also improvement or lack of change, and to prevent negative priming. If a bipolar format is not appropriate to the content, a 4-stage unipolar response format is applied instead ($0 = “disagree/not applicable”$ to $3 = “fully agree”). For each item, the attribution is stated from the patient’s perspective (“What caused this outcome?” – “the therapy” or “other circumstances in life”). Only negative effects that are attributed by the patient directly to the psychotherapeutic treatment are considered for the analysis.

Health service use will be measured using the FIMPsy questionnaire which is particularly suited for patients with mental disorders [71, 76]. It assesses the following services in the preceding six months retrospectively: psychiatric counselling, assisted living, and occupational integration. FIMPsy also captures contacts with outpatient and inpatient medical providers as well as the intake of medication.

**Process evaluation**

First, to enrich the outcome data collected in the RCT by understanding the context in which the outcomes developed, we will conduct a parallel process evaluation featuring individual qualitative semi-guided interviews with patients, GPs, practice staff, and MHS [77]. Participants will be sampled purposively according to characteristics anticipated to influence implementation and outcomes. We will focus the interviews on barriers and facilitators for implementing the model. Applying a during-trial design nested in the RCT, we will collect process data at the various stages of the intervention, that is early in the course of the intervention, during the intervention and after the intervention [78]. Specifically, we will use the domains (1) quality of implementation, (2) causal mechanisms/pathways, and (3) contextual influences on the implementation of the intervention as main top-down themes for thematic analysis of the interview data. We will also use the findings from the feasibility trial to inform the process evaluation. Coders conducting the qualitative analysis will not be involved in the delivery of the intervention and analyse the qualitative data prior to knowing the trial outcomes. Second, we will provide detailed information on participant retention per video consultation (e.g., average number of completed video consultations, number of participants who were allocated to the intervention but never started the video consultations). Finally, as part of a pre–post-study measurement of intervention implementability, all practice teams and MHS will fill in the Normalisation MeAsure Development (NoMAD) questionnaire prior to inclusion of the first patient and close-out of the last patient [79]. Specifically, the NoMAD assesses health professionals’ perceptions of factors relevant to embedding interventions that change their work practices.
Retention

We will continuously monitor the trial for any operational issues (i.e., failure in appointment management, no-show of patients) by timely and directly communicating with the enrolled practices. Concerning data collection, we will prioritise short questionnaires to reduce participant burden. To encourage retention at each study timepoint, nonresponders will receive up to five reminders in total via phone, mail, and e-mail. For the baseline survey, these reminders will also provide the option of completing the assessment over the phone. For the six- and 12-month survey, these reminders will offer the option of being mailed a hard copy of the questionnaire to complete and return via reply paid envelope and/or filling in the PHQ-ADS alone. Outcome assessments may be completed in multiple sittings.

Data management

We will enter data from mail survey (baseline) and CATIs (six- and 12-month survey) on the password-protected online survey tool (Enterprise Feedback Suite (EFS) Survey, Questback GmbH) and enforce data integrity using forced or multiple-choice items wherever possible. A member of the research team will regularly check all data to identify and, where possible, resolve errors prior to analyses being conducted (e.g., by conducting range and plausibility checks). Data preparation prior to the main analysis will be conducted by two members of the research team independently. We will keep all data for 10 years after study completion after which time they will be destroyed in accordance with the recommendations of the Medical Faculty of the University of Heidelberg Ethics Committee. All computers and servers used to manage contact with participants and track progress through the study will be password-protected and housed in a secure environment at Heidelberg University; only the study team will have access to the identified data.

Statistical methods

Descriptive statistics (absolute and relative frequencies for variables with nominal and measures of position (mean, median) and variability measures (standard deviation, interquartile range, and range) for variables with interval or ratio scaling) will be used to compare participant characteristics between the study arms.

For the analysis of the primary outcome, we will use the complete and pseudonymized data set and follow the intention-to-treat approach which includes all patients in the group they were allocated to by randomisation. In a sensitivity analysis, we will evaluate the per-protocol population in which only patients who will have participated in at least three video consultations (defined as engagement in video consultations) will be included. The null hypothesis for the primary outcome is: The absolute change in depressive and anxiety symptom severity from baseline to post assessment (6 months after baseline assessment) is the same in both groups. Provided that the model assumptions are fulfilled, the null hypothesis will be tested using a (robust) mixed linear regression model at a significance level of 5% [80]. In addition to the group variable, the regression model will contain the following variables at baseline: depressive and anxiety symptom severity, history of depression/anxiety, physical health status, chronic
medical disease, gender, age (fixed effects) and trial site (general practice) (random effect). We will compute effect sizes and interpret them together with the respective 95% confidence intervals [81]. The analyses of the secondary outcomes will be purely exploratory and analogous to the analysis of the primary outcome. We will conduct subgroup analyses with respect to equality of the subgroups for the main and secondary objective criteria applying (robust) mixed linear regression models, which will also contain an interaction term between the study arm (intervention vs. comparison) and the subgroup to be investigated. The corresponding \( p \)-values of these tests will be interpreted purely descriptively. If subjects discontinue the study, they will be described separately to provide clues as to possible selectivity. The entire statistical evaluation will be performed in R (version 4.0.2 or higher) [82]. Prior to all analyses, we will pre-specify a statistical analysis plan.

**Missing data**

Applying the participant retention strategies outlined above, we will try to minimise the missing outcome data. Notwithstanding, we will record reasons participants are lost to follow-up. Prior to multiple imputation of missing values for primary and secondary outcomes at the item level, we will conduct sensitivity analyses to assess the robustness of the missing data assumption [83].

*Cost-effectiveness and cost-utility analysis*

To investigate economic efficiency of primary care embedded MHSVC model of care compared to usual care, a health economic evaluation in form of a cost-effectiveness analysis (CEA) and a cost-utility analysis (CUA) is carried out. The CEA will estimate an incremental cost-effectiveness ration (ICER) in terms of additional costs per additional person who experienced a minimal important decrease at the PHQ-ADS of 5 points and additional costs per additional person below the threshold of 10 at the PHQ-ADS implying less than mild depressive and anxiety symptom severity (6 months after baseline assessment). The CUA yields an incremental cost-utility ratio (ICUR) as additional costs per improvement in QALYs. The QALYs are based on the EQ-5D-5L an established preference-based instrument for measuring quality-of-life and evaluated by a German tariff to generate utilities [75, 84].

The health economic evaluation will be performed from a societal perspective. The effect parameter is deduced from the primary outcome and will be taken from the trial. Intervention related costs (e.g. MHS salaries) are taken from the study documentation. Costs regarding inpatient and outpatient health care use, psychiatric counselling, assisted living, occupational integration, absent days, and antipsychotic medication are assessed at baseline, six and 12 months after baseline referring to either the last six month by a standardised instrument [71]. This questionnaire was also used in the feasibility trial (PROVIDE-B) [44] and deemed to be applicable in the efficiency trial to assess resource use. Resource use will be multiplied by prices obtained by published sources and official statistics for Germany. Indirect costs will be evaluated by the human capital approach [85]. Discounting is not required due to the short intervention period.
According to the statistical analysis, we follow the intention-to-treat approach and use multiple imputation to deal with missing data. The ICER and ICUR will be calculated and the non-parametric bootstrap method will be employed to generate 95% confidence intervals [86, 87]. To account for uncertainty, results will be presented on the cost-effectiveness plane and as cost-effectiveness acceptability curve [88–91]. The health economic evaluation will be performed using Stata 15.1.

**Monitoring**

To monitor our study a Steering Committee (SC) and a Data Monitoring (DMC) will be appointed. The SC will comprise all researchers involved in this publication and will be led by MH, an experienced researcher with expertise in clinical research. On regular meetings the SC will monitor the study procedures and ensure that the trial is being conducted according to the study protocol. On this behalf, areas of interest are the recruitment processes of all different participants (patients, MHS, GP), intervention delivery, data collection, and communication aspects with both the collaboration partners and the trial participants. Primary aim of the SC is to facilitate the smooth running of the trial.

The DMC will comprise four members including one researcher from the Institute of Medical Biometry and Informatics in Heidelberg. They will have clinical, research and statistical expertise. They will regularly monitor quality and plausibility of the collected data by sighting data exports from the electronic data collection platform. In light of the fact that the intervention used in our trial study is evidence-based, successfully piloted, and all patients will be linked in with their GP, no interim analyses or auditing are planned. Close communication with the MHS additionally to the biweekly supervision will assess adverse events. We will record all adverse events with respect to relation to study, severity, potential for the event to have been anticipated, and action taken. Serious adverse events will be reported to the Ethics Committee.

**Ethics**

This trial has undergone ethical scrutiny and has been approved by the Medical Faculty of the University of Heidelberg Ethics Committee (S-923/2019). Additionally, considering that the study will take place in routine general practice, we have obtained the ethical approval of the State Chamber of Physicians Baden-Wuerttemberg. Approvals from Hesse and Rhineland-Palatinate, where recruitment will start later, are pending. Eligible patients will receive a hardcopy of a plain language statement outlining the potential risks and benefits of participating in the PROVIDE-C trial and give written informed consent to participate in the study. Confidentiality of participants will be protected by assignment of an identification number to each participant. Participants’ study information will not be released outside of the study without permission, except where maintaining confidentiality endangers the health or safety of the participant or someone else.

After the individual intervention period, all patients, who need further psychological treatment or mental health support, can approach the psychosomatic outpatient clinic at the University Hospital Heidelberg.
Furthermore, one main component of the intervention is the consideration and discussion between MHS and patient about the type of a potential follow-up treatment.

**Dissemination policy**

Regardless of the magnitude or direction of effect, the results of this trial will be presented at relevant national and international conferences and as published articles in peer-reviewed journals. Publication of the study results will be based on the CONSORT-SPI 2018 statement for social and psychological interventions and the CONSORT extension for adverse effects [43, 92]. The progress and the results of the trial will be disseminated to the participating general practices and MHS in a trial newsletter and via personal visits and to patients, caregivers, and wider audiences via social media. To reach health care policy and practice audiences (e.g., government bodies) concerning the scale-up of the model, we will present the findings at policy maker- and service provider-run conferences. Aiming at directly informing the work of policy makers and practitioners, we will report the findings in plain language formats to them and compile an executive summary drawing together key findings of all aspects of the intervention with a series of journal articles included as appendices.

**Discussion**

Although an array of effective treatments is available, depression and anxiety disorders still cause a notable burden to many people worldwide. In contrast to traditional specialised services, mental health service models integrated into primary care succeed in engaging hard-to-reach patient groups where they enter the health care system. However, models with mental health specialists located on site are not feasible for the large number of smaller, single-handed and/or rural or remote general practices in many countries throughout the world. Instead, primary care mental health featuring MHSVC may be more suitable for these practices and increase the accessibility to specialised mental health care for the increasing number of multimorbid patients.

We have therefore developed and piloted a service model that integrates MHSVC into primary care for treating patients presenting with depression and anxiety. In the PROVIDE-C trial, we will test whether this model is a clinically effective and cost-efficient way of reducing depressive and anxiety symptom severity, relative to usual care. The main strength of this trial is its sound foundation in both a preimplementation and a feasibility study and the resulting feedback from the key stakeholders. Although the trial is performed in routine practice settings, we will optimise the likelihood of treatment effectiveness by strict inclusion criteria for patients and enhanced intervention integrity. Challenges of this trial may include the recruitment and retention of patients [93]. If the PROVIDE model proves to be clinically effective and cost-effective, broad implementation into routine primary care could contribute to mitigating the geographical and temporal barriers for optimised diagnostics and treatment for two of the most pressing health conditions globally.

**Trial Status**
At the time of submission, patient recruitment to the PROVIDE-C trial is ongoing. The anticipated study completion date is November 2023. This trial was prospectively registered on ClinicalTrials.gov with study ID NCT04316572 on March 20th, 2020.

**Abbreviations**

CATI: Computer Assisted Telephone Interview; CC: collaborative care; CONSORT-SPI: CONSORT 2010 Statement for Social and Psychological Interventions Statement; DSM-5: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; EFS: Enterprise Feedback Suite; FIMPsy: Questionnaire for the Assessment of Medical and non-Medical Resource Utilisation in Mental Disorders; GAD-7: Generalized Anxiety Disorder–7 Scale; GP: general practitioner; HIP: Heidelberg Institute for Psychotherapy; ICER: incremental cost-effectiveness ratio; INEP: Inventory for the Assessment of Negative Effects of Psychotherapy; ITT: intention-to-treat; MHS: mental health specialist; MHSVC: mental health specialist video consultation; NoMAD: Normalisation MeAsure Development; PACIC–Short Form: Patient Assessment of Chronic Illness Care –Short Form; PCBH: primary care behavioural health; PHQ-ADS: Patient Health Questionnaire Anxiety and Depression Scale; PHQ-9: Patient Health Questionnaire–9; PROVIDE: ImPROving cross-sectoral collaboration between primary and psychosocial care: An implementation study on VIDEo consultations; RAS-G: Recovery Assessment Scale German Version; RCT: randomised controlled trial; SSD-12: Somatic Symptom Disorder–B Criteria Scale; SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials; TIDieR: Template for Intervention Description and Replication; US: United States

**Declarations**

**ACKNOWLEDGEMENTS**

We would like to thank Mariell Hoffmann, PhD student, Department of General Internal Medicine and Psychosomatics, Heidelberg University, and Iris Schelletter, study nurse, Department of General Internal Medicine and Psychosomatics, Heidelberg University, for contributing to the preimplementation (PROVIDE-A) and feasibility (PROVIDE-B) studies and Alina Wildenauer, MA, for editing the manuscript.

**AUTHORS’ CONTRIBUTIONS**

All authors contributed substantially to the conception and the design of the study. MWH, JT, MH, RB, DW, MW, JS, MV, AI and MH contributed to data analysis plan. MWH, JT, MH, and HCF drafted the manuscript. All authors including RB, DW, MW, MV, AI, BW, and HCF revised the manuscript critically for important intellectual content. All authors approved the version of the manuscript to be published and have agreed to be accountable for all aspects of the work. Regarding the selection of authors, we followed the guidance of the Committee on Publication Ethics (COPE).

**FUNDING**
This work was supported entirely by the German Federal Ministry of Education and Research (BMBF) (grant no. 01GY16129). The funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report.

**AVAILABILITY OF DATA AND MATERIALS**

Not applicable.

**ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

This trial has undergone ethical scrutiny and has been approved by the Medical Faculty of the University of Heidelberg Ethics Committee (S-923/2019). Additionally, considering that the study will take place in routine general practice, we have obtained the ethical approval of the State Chamber of Physicians Baden-Wuerttemberg. Approvals from Hesse and Rhineland-Palatinate, where recruitment will start later, are pending. Written, informed consent to participate will be obtained from all participants.

**CONSENT FOR PUBLICATION**

Not applicable.

**COMPETING INTERESTS**

No authors have competing interests to declare. During the trial, all authors will comply with their respective institution’s policies on conflicts of interest.

**References**

1. World Health Organization. Depression and other common mental disorders: global health estimates. World Health Organization; 2017 p. 24 p.

2. Vos T, Barber RM, Bell B, Bertozzi-Villa A, Biryukov S, Bolliger I, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015;386:743–800.

3. Patel V, Chisholm D, Parikh R, Charlson FJ, Degenhardt L, Dua T, et al. Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. The Lancet. Elsevier; 2016;387:1672–85.

4. Cunningham PJ. Beyond Parity: Primary Care Physicians’ Perspectives On Access To Mental Health Care. Health Aff (Millwood). 2009;28:w490–501.

5. Wang PS, Lane M, Olfson M, Pincus HA, Wells KB, Kessler RC. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:629–40.
6. Thornicroft G, Chatterji S, Evans-Lacko S, Gruber M, Sampson N, Aguilar-Gaxiola S, et al. Undertreatment of people with major depressive disorder in 21 countries. Br J Psychiatry. 2017;210:119–24.

7. Greenhalgh T, Shaw S, Wherton J, Vijayaraghavan S, Morris J, Bhattacharya S, et al. Real-World Implementation of Video Outpatient Consultations at Macro, Meso, and Micro Levels: Mixed-Method Study. J Med Internet Res. 2018;20:e150.

8. Angermeyer MC, Auwera S van der, Carta MG, Schomerus G. Public attitudes towards psychiatry and psychiatric treatment at the beginning of the 21st century: a systematic review and meta-analysis of population surveys. World Psychiatry. 2017;16:50–61.

9. Rechel B, Grundy E, Robine J-M, Cylus J, Mackenbach JP, Knai C, et al. Ageing in the European Union. The Lancet. 2013;381:1312–22.

10. Wang PS, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Borges G, Bromet EJ, et al. Use of mental health services for anxiety, mood, and substance disorders in 17 countries in the WHO world mental health surveys. Lancet Lond Engl. 2007;370:841–50.

11. Cunningham PJ. Beyond Parity: Primary Care Physicians’ Perspectives On Access To Mental Health Care. Health Aff (Millwood). 2009;28:w490–501.

12. Gaebel W, Kowitz S, Fritze J, Zielasek J. Use of health care services by people with mental illness: secondary data from three statutory health insurers and the German Statutory Pension Insurance Scheme. Dtsch Arzteblatt Int. 2013;110:799–808.

13. Lester H, Tritter JQ, Sorohan H. Patients’ and health professionals’ views on primary care for people with serious mental illness: focus group study. BMJ. 2005;330:1122.

14. Kendrick T, King F, Albertella L, Smith PW. GP treatment decisions for patients with depression: an observational study. Br J Gen Pract. 2005;55:280–6.

15. Trautmann S, Beesdo-Baum K. The Treatment of Depression in Primary Care. Dtsch Ärztebl Int. 2017;114:721–8.

16. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. The Lancet. 2007;370:851–8.

17. Ring A, Dowrick CF, Humphris GM, Davies J, Salmon P. The somatising effect of clinical consultation: what patients and doctors say and do not say when patients present medically unexplained physical symptoms. Soc Sci Med 1982. 2005;61:1505–15.

18. Hoffmann M, Hartmann M, Wensing M, Friederich H-C, Haun MW. Potential for Integrating Mental Health Specialist Video Consultations in Office-Based Routine Primary Care: Cross-Sectional Qualitative Study Among Family Physicians. J Med Internet Res Canada. 2019;21:e13382.

19. Crowley RA, Kirschner N. The integration of care for mental health, substance abuse, and other behavioral health conditions into primary care: Executive summary of an american college of physicians position. Ann Intern Med. 2015;163:298–9.

20. Archer J, Bower P, Gilbody S, Lovell K, Richards D, Gask L, et al. Collaborative care for depression and anxiety problems. Cochrane Database Syst Rev. 2012;10:CD006525.
21. Coventry PA, Hudson JL, Kontopantelis E, Archer J, Richards DA, Gilbody S, et al. Characteristics of effective collaborative care for treatment of depression: a systematic review and meta-regression of 74 randomised controlled trials. PloS One. 2014;9:e108114.

22. Reiter JT, Dobmeyer AC, Hunter CL. The Primary Care Behavioral Health (PCBH) Model: An Overview and Operational Definition. J Clin Psychol Med Settings. 2018;25:109–26.

23. Kanapaux W. The road to integrated care: commitment is the key; Tennessee CMHC demonstrates promise of co-located behavioral and primary care. Behav Healthc Tomorrow. 2004;13:10–5.

24. Miller-Matero LR, Khan S, Thiem R, DeHondt T, Dubaybo H, Moore D. Integrated primary care: patient perceptions and the role of mental health stigma. Prim Health Care Res Dev. 2018;20:1–4.

25. Sandoval BE, Bell J, Khatri P, Robinson PJ. Toward a Unified Integration Approach: Uniting Diverse Primary Care Strategies Under the Primary Care Behavioral Health (PCBH) Model. J Clin Psychol Med Settings. 2018;25:187–96.

26. Richards DA, Hill JJ, Gask L, Lovell K, Chew-Graham C, Bower P, et al. Clinical effectiveness of collaborative care for depression in UK primary care (CADET): cluster randomised controlled trial. BMJ. 2013;347:f4913.

27. Gensichen J, von Korff M, Peitz M, Muth C, Beyer M, Güthlin C, et al. Case management for depression by health care assistants in small primary care practices. Ann Intern Med. 2009;151:369–80.

28. Schoen C, Osborn R, Doty MM, Squires D, Peugh J, Applebaum S. A survey of primary care physicians in eleven countries, 2009: Perspectives on care, costs, and experiences. Health Aff (Millwood). 2009;28:1171–83.

29. Kringos DS, Boerma WGW, Hutchinson A, Saltman RB. Building primary care in a changing Europe case studies [Internet]. 2015 [cited 2020 May 31]. Available from: http://www.euro.who.int/en/about-us/partners/observatory/publications/studies/building-primary-care-in-a-changing-europe-case-studies.

30. Fortney JC, Pyne JM, Turner EE, Farris KM, Normoyle TM, Avery MD, et al. Telepsychiatry integration of mental health services into rural primary care settings. Int Rev Psychiatry. 2015;27:525–39.

31. Hilty DM, Rabinowitz T, McCarron RM, Katzelnick DJ, Chang T, Bauer AM, et al. An update on telepsychiatry and how it can leverage collaborative, stepped, and integrated services to primary care. Psychosomatics. 2018;59:227–50.

32. Hilty DM, Yellowlees PM, Cobb HC, Bourgeois JA, Neufeld JD, Nesbitt TS. Models of telepsychiatric consultation—liaison service to rural primary care. Psychosomatics. 2006;47:152–7.

33. Ratzliff A, Sunderji N. Tele-Behavioral, Health. Collaborative Care, and Integrated Care: Learning to Leverage Scarce Psychiatric Resources over Distance, Populations, and Time. Acad Psychiatry. 2018;42:834–40.

34. Hilty DM, Sunderji N, Suo S, Chan S, McCarron RM. Telepsychiatry and other technologies for integrated care: evidence base, best practice models and competencies. Int Rev Psychiatry. 2018;30:292–309.
35. Massoudi B, Holvast F, Bockting CLH, Burger H, Blanker MH. The effectiveness and cost-effectiveness of e-health interventions for depression and anxiety in primary care: A systematic review and meta-analysis. J Affect Disord Netherlands. 2019;245:728–43.

36. Turvey C, Fortney J. The Use of Telemedicine and Mobile Technology to Promote Population Health and Population Management for Psychiatric Disorders. Curr Psychiatry Rep United States. 2017;19:88.

37. Fortney JC, Pyne JM, Edlund MJ, Williams DK, Robinson DE, Mittal D, et al. A randomized trial of telemedicine-based collaborative care for depression. J Gen Intern Med. 2007;22:1086–93.

38. Fortney JC, Pyne JM, Kimbrell TA, et al. Telemedicine-based collaborative care for posttraumatic stress disorder: A randomized clinical trial. JAMA Psychiatry. 2015;72:58–67.

39. Morriss R, Patel S, Malins S, Guo B, Higton F, James M, et al. Clinical and economic outcomes of remotely delivered cognitive behaviour therapy versus treatment as usual for repeat unscheduled care users with severe health anxiety: a multicentre randomised controlled trial. BMC Med. 2019;17:16.

40. Tönnies J, Hartmann M, Wensing M, Szecsenyi J, Icks A, Friederich H-C, et al. Mental health specialist video consultations for patients with depression or anxiety disorders in primary care: protocol for a randomised controlled feasibility trial. BMJ Open. 2019;9:e030003.

41. Haun MW, Hoffmann M, Tönnies J, Wensing M, Szecsenyi J, Brinster R, et al. Mental health specialist video consultations for managing depression and anxiety in primary care: A qualitative study nested within a randomized controlled pilot study to assess implementation quality.

42. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.

43. Montgomery P, Grant S, Mayo-Wilson E, Macdonald G, Michie S, Hopewell S, et al. Reporting randomised trials of social and psychological interventions: the CONSORT-SPI 2018 Extension. Trials. 2018;19:407.

44. Cavelti M, Wirtz M, Corrigan P, Vauth R. Recovery assessment scale: Examining the factor structure of the German version (RAS-G) in people with schizophrenia spectrum disorders. Eur Psychiatry. 2017;41:60–7.

45. INVOLVE. Briefing notes for researchers: involving the public in NHS, public health and social care research. Eastleigh: INVOLVE; 2012.

46. Kroenke K, Spitzer RL, Williams JB, Löwe B. The patient health questionnaire somatic, anxiety, and depressive symptom scales: a systematic review. Gen Hosp Psychiatry. 2010;32:345–59.

47. Bower P, Gask L. The changing nature of consultation-liaison in primary care: bridging the gap between research and practice. Gen Hosp Psychiatry. 2002;24:63–70.

48. Craske MG. Transdiagnostic Treatment for Anxiety and Depression. Depress Anxiety. 2012;29:749–53.

49. Newby JM, McKinnon A, Kuyken W, Gilbody S, Dalgleish T. Systematic review and meta-analysis of transdiagnostic psychological treatments for anxiety and depressive disorders in adulthood. Clin
50. Zhang A, Franklin C, Jing S, Bornheimer LA, Hai AH, Himle JA, et al. The effectiveness of four empirically supported psychotherapies for primary care depression and anxiety: A systematic review and meta-analysis. J Affect Disord. 2019;245:1168–86.

51. Fonagy P. Achieving Evidence-Based Psychotherapy Practice: A Psychodynamic Perspective on the General Acceptance of Treatment Manuals. Clin Psychol Sci Pract. 1999;6:442–4.

52. Carroll KM, Nuro KF. One Size Cannot Fit All: A Stage Model for Psychotherapy Manual Development. Clin Psychol Sci Pract. 2002;9:396–406.

53. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687.

54. Mark TL, Levit KR, Buck JA. Datapoints: psychotropic drug prescriptions by medical specialty. Psychiatr Serv. 2009;60:1167–7.

55. Marcus SC, Olfson M. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiatry. 2010;67:1265.

56. Kilbourne AM, Neumann MS, Pincus HA, Bauer MS, Stall R. Implementing evidence-based interventions in health care: application of the replicating effective programs framework. Implement Sci. 2007;2:42.

57. Bellg AJ, Borrelli B, Resnick B, Hecht J, Minicucci DS, Ory M, et al. Enhancing treatment fidelity in health behavior change studies: best practices and recommendations from the nih behavior change consortium. Health Psychol. 2004;23:443–51.

58. Bower P, Gilbody S, Richards D, Fletcher J, Sutton A. Collaborative care for depression in primary care. Making sense of a complex intervention: systematic review and meta-regression. Br J Psychiatry. 2006;189:484–93.

59. Diener MJ, Hilsenroth MJ, Weinberger J. Therapist affect focus and patient outcomes in psychodynamic psychotherapy: a meta-analysis. Am J Psychiatry. 2007;164:936–41.

60. Allen JD, Shelton RC, Emmons KM, Linnan LA. Fidelity and its relationship to implementation effectiveness, adaptation, and dissemination. In: Brownson RC, Colditz GA, Proctor EK, editors. Dissem Implement Res Health - Transl Sci Pract. New York: Oxford University Press; 2018. pp. 267–84.

61. Kroenke K, Wu J, Yu Z, Bair MJ, Kean J, Stump T, et al. Patient health questionnaire anxiety and depression scale: initial validation in three clinical trials. Psychosom Med. 2016;78:716–27.

62. Chilcot J, Hudson JL, Moss-Morris R, Carroll A, Game D, Simpson A, et al. Screening for psychological distress using the Patient Health Questionnaire Anxiety and Depression Scale (Phq-ads): Initial validation of structural validity in dialysis patients. Gen Hosp Psychiatry. 2018;50:15–9.

63. Kroenke K, Baye F, Lourens SG. Comparative validity and responsiveness of PHQ-ADS and other composite anxiety-depression measures. J Affect Disord. 2019;246:437–43.
64. Vickers AJ, Altman DG. Statistics Notes: Analysing controlled trials with baseline and follow up measurements. BMJ. 2001;323:1123–4.

65. Gunn J, Elliott P, Densley K, Middleton A, Ambresin G, Dowrick C, et al. A trajectory-based approach to understand the factors associated with persistent depressive symptoms in primary care. J Affect Disord. 2013;148:338–46.

66. Toussaint A, Murray AM, Voigt K, Herzog A, Gierk B, Kroenke K, et al. Development and Validation of the Somatic Symptom Disorder–B Criteria Scale (SSD-12). Psychosom Med. 2016;78:5–12.

67. Ware JE Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996;220–33.

68. Greiner W, Claes C, Busschbach JJV, von der Schulenburg JMG. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ. 2005;6:124–30.

69. Goetz K, Freund T, Gensichen J, Miksch A, Szecsenyi J, Steinhaeuser J. Adaptation and psychometric properties of the PACIC short form. Am J Manag Care. 2012;18:e55–60.

70. Ladwig I, Rief W, Nestoriuc Y. Welche Risiken und Nebenwirkungen hat Psychotherapie?-Entwicklung des Inventars zur Erfassung Negativer Effekte von Psychotherapie (INEP). Verhaltenstherapie. 2014;24:252–63.

71. Grupp H, König H-H, Riedel-Heller S, Konnopka A. FIMPsy–Fragebogen zur Inanspruchnahme medizinischer und nicht medizinischer Versorgungsleistungen bei psychischen Erkrankungen: Entwicklung und Verwendung. Psychiatr Prax. 2018;45:87–94.

72. Salisbury C, O’Cathain A, Edwards L, Thomas C, Gaunt D, Hollinghurst S, et al. Effectiveness of an integrated telehealth service for patients with depression: a pragmatic randomised controlled trial of a complex intervention. Lancet Psychiatry England. 2016;3:515–25.

73. Ioannidis JPA. Most psychotherapies do not really work, but those that might work should be assessed in biased studies. Epidemiol Psychiatr Sci. 2016;25:436–8.

74. Hüsing P, Bassler M, Löwe B, Koch S, Toussaint A. Validity and sensitivity to change of the somatic symptom disorder–b criteria scale (SSD-12) in a clinical population. Gen Hosp Psychiatry. 2018;55:20–6.

75. Ludwig K, Graf von der Schulenburg JM, Greiner W. German value set for the eq-5d-5 l. Pharmacoeconomics. 2018;36:663–74.

76. Chernyak N, Ernsting C, Icks A. Pre-test of questions on health-related resource use and expenditure, using behaviour coding and cognitive interviewing techniques. BMC Health Serv Res. 2012;12:303.

77. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. BMJ. 2015;350:h1258–8.

78. Atkins S, Odendaal W, Leon N, Lutge E, Lewin S. Qualitative process evaluation for complex interventions. In: Richards DA, Hallberg IR, editors. Complex Interv Health. New York: Routledge; 2015. pp. 239–47.
79. Vis C, Ruwaard J, Finch T, Rapley T, de Beurs D, van Stel H, et al. Toward an objective assessment of implementation processes for innovations in health care: psychometric evaluation of the normalization measure development (Nomad) questionnaire among mental health care professionals. J Med Internet Res. 2019;21:e12376.

80. Koller M. robustlmm: an r package for robust estimation of linear mixed-effects models. J Stat Softw. 2016;75.

81. Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. Front Psychol. 2013;4.

82. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available from: https://www.R-project.org/.

83. van Buuren S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat Methods Med Res. 2007;16:219–42.

84. Drummond MF. Methods for the economic evaluation of health care programmes. 3. ed., reprint. Drummond MF, editor. Oxford: Oxford University Press; 2007.

85. Gold MR, editor. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.

86. Hunink MGM, Bult JR, De Vries J, Weinstein MC. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making. 1998;18:337–46.

87. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997;6:327–40.

88. Black WC. The ce plane: a graphic representation of cost-effectiveness. Med Decis Making. 1990;10:212–4.

89. Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves—facts, fallacies and frequently asked questions. Health Econ. 2004;13:405–15.

90. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ. 2001;10:779–87.

91. Van Hout BA, Al MJ, Gordon GS, Rutten FFH. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994;3:309–19.

92. Ioannidis JPA. Better reporting of harms in randomized trials: an extension of the consort statement. Ann Intern Med. 2004;141:781.

93. Edwards L, Salisbury C, Horspool K, Foster A, Garner K, Montgomery AA. Increasing follow-up questionnaire response rates in a randomized controlled trial of telehealth for depression: three embedded controlled studies. Trials. 2016;17:107.